WAVEMAN · COMPANY

BTAI · Bioxcel Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

BTAI

Name: BioXcel Therapeutics, Inc. (BTAI) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BioXcel Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001720893

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$43.2K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-71.7%

XBRL, annual

NET MARGIN

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$43.2K over 180 days

more than 59% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

22 funds added or opened last quarter

below 68% of Pharma & Biotech

REVENUE

-71.7% year over year

below 88% of Pharma & Biotech

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

13.5% of shares outstanding short · 9.7 days to cover · settled 2026-07-31

more than 87% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$43.2K across 4 people in 180 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -98.1%

-98.1%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $43.2K sold by insiders over 180 days, 22 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BioXcel Therapeutics, Inc. insiders sold a net $43.2K of stock across 74 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Yocca Frank

Chief Scientific Officer

SELL

2026-05-20

6,845.0

$7.5K

Rodriguez Javier

See Remarks

SELL

2026-05-20

6,560.0

$7.1K

Steinhart Richard I

Chief Financial Officer

SELL

2026-05-20

6,845.0

$7.5K

Mehta Vimal

CEO and President

SELL

2026-05-20

19,419.0

$21.2K

O'Neill Vincent

See Remarks

SELL

2024-12-16

165.0

$58

74 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 69 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

MILLENNIUM MANAGEMENT LLC

2,114,710.0 sh

$3.0M

OAKTREE CAPITAL MANAGEMENT LP

1,380,248.0 sh

$1.9M

VANGUARD CAPITAL MANAGEMENT LLC

919,545.0 sh

$1.3M

Oaktree Fund Advisors, LLC

245,585.0 sh

$346.3K

GEODE CAPITAL MANAGEMENT, LLC

242,251.0 sh

$341.9K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Select Biotechnology Portfolio

$150.8K POSITION · AS OF 2026-02-28

0.0%

Fidelity Extended Market Index Fund

$176.2K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$277.8K POSITION · AS OF 2026-03-31

0.0%

Total Stock Market Index Trust

$586 POSITION · AS OF 2026-03-31

0.0%

Fidelity Total Market Index Fund

$57.2K POSITION · AS OF 2026-02-28

0.0%

Fidelity Series Total Market Index Fund

$44.4K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 15 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Phase 2

0 ACTIVE

Phase 3

0 ACTIVE

Phase 4

0 ACTIVE

Early Phase 1

0 ACTIVE

Multi-phase

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$642.0K	$2.3M	$1.4M	$375.0K
OPERATING INCOME	$-50.5M	$-67.2M	$-171.8M	$-159.6M
NET INCOME	$-69.9M	$-59.6M	$-179.1M	$-165.8M
EPS (DILUTED)	-5.73	-23.51	-98.33	-5.92
OPERATING CASH FLOW	$-57.6M	$-72.0M	$-155.0M	$-135.3M
CASH	$28.4M	$29.9M	$65.2M	$193.7M
LONG-TERM DEBT	$84.7M	$102.5M	$100.6M	$93.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE